Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer

Laurence H. Baker, Michael I. Opipari, Henry Wilson, Richard Bottomley, Charles A. Coltman

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


The Southwest Oncology Group has treated 130 patients with advanced disseminated uterine cervical carcinoma no longer amenable to therapy with further radiation or surgery. Patients received one of three different schedules of mitomycin C, vincristine and bleomycin. A twice weekly schedule of bleomycin and vincristine produced response in 60% of patients. An infusion bleomycin schedule produced response in 39% of patients and a once weekly vincristine bleomycin schedule produced a 25% response rate (45% overall). Responding patients lived significantly longer than nonresponders (30 vs 18 weeks). Toxicities encountered included leukopenia, thrombocytopenia, peripheral neuropathy, gastrointestinal upset, dermatitis, and alopecia. We believe two of the schedules utilized represent an improvement in producing tumor remission induction in this previously recognized refractory carcinoma.

Original languageEnglish (US)
Pages (from-to)146-150
Number of pages5
JournalObstetrics and gynecology
Issue number2
StatePublished - Aug 1978
Externally publishedYes

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer'. Together they form a unique fingerprint.

Cite this